A PET-based nomogram for oropharyngeal cancers.
- Castelli J Radiotherapy Department, Lausanne University Hospital, Switzerland; INSERM, U1099, Rennes, F-35000, France; Université de Rennes 1, LTSI, Rennes, F-35000, France.
- Depeursinge A Ecole Polytechnique Fédérale de Lausanne, CH-1015, Lausanne, VD, Switzerland; University of Applied Sciences Western Switzerland, 3960, Sierre, Switzerland.
- Ndoh V Radiotherapy Department, Centre Eugene Marquis, Rennes, F-35000, France.
- Prior JO Nuclear Medicine and Molecular Imaging Department, Lausanne University Hospital, Switzerland.
- Ozsahin M Radiotherapy Department, Lausanne University Hospital, Switzerland.
- Devillers A Nuclear Medicine Department, Centre Eugene Marquis, Rennes, F-35000, France.
- Bouchaab H Radiotherapy Department, Lausanne University Hospital, Switzerland.
- Chajon E Radiotherapy Department, Centre Eugene Marquis, Rennes, F-35000, France.
- de Crevoisier R Radiotherapy Department, Centre Eugene Marquis, Rennes, F-35000, France.
- Scher N Radiotherapy Department, Lausanne University Hospital, Switzerland.
- Jegoux F Head and Neck Department, CHU Rennes, Rennes, F-35000, France.
- Laguerre B Oncology Department, Centre Eugene Marquis, Rennes, F-35000, France.
- De Bari B Radiotherapy Department, Lausanne University Hospital, Switzerland.
- Bourhis J Radiotherapy Department, Lausanne University Hospital, Switzerland. Electronic address: Jean.Bourhis@chuv.ch.
- 2017-02-27
Published in:
- European journal of cancer (Oxford, England : 1990). - 2017
Nomogram
Oropharyngeal cancer
PET
Prognostic score
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Cetuximab
Chemoradiotherapy
Cisplatin
Female
Humans
Male
Middle Aged
Neoplasm Staging
Nomograms
Oropharyngeal Neoplasms
Positron Emission Tomography Computed Tomography
Prognosis
Radiotherapy, Intensity-Modulated
Young Adult
English
PURPOSE
In the context of locally advanced oropharyngeal cancer (LAOC) treated with definitive radiotherapy (RT) (combined with chemotherapy or cetuximab), the aims of this study were: (1) to identify PET-FDG parameters correlated with overall survival (OS) from a first cohort of patients; then (2) to compute a prognostic score; and (3) finally to validate this scoring system in a second independent cohort of patients.
MATERIALS AND METHODS
A total of 76 consecutive patients (training cohort from Rennes) treated with chemoradiotherapy or RT with cetuximab for LAOC were used to build a predictive model of locoregional control (LRC) and OS based on PET-FDG parameters. After internal calibration and validation of this model, a nomogram and a scoring system were developed and tested in a validation cohort of 46 consecutive patients treated with definitive RT for LAOC in Lausanne.
RESULTS
In multivariate analysis, the metabolic tumour volume (MTV) of the primary tumour and the lymph nodes were independent predictive factors for LRC and OS. Internal calibration showed a very good adjustment between the predicted OS and the observed OS at 24 months. Using the predictive score, two risk groups were identified (median OS 42 versus 14 months, p < 0.001) and confirmed in the validation cohort from Lausanne (median OS not reached versus 26 months, p=0.008).
CONCLUSIONS
This is the first report of a PET-based nomogram in oropharyngeal cancer. Interestingly, it appeared stronger than the classical prognostic factors and was validated in independent cohorts markedly diverging in many aspects, which suggest that the observed signal was robust.
In the context of locally advanced oropharyngeal cancer (LAOC) treated with definitive radiotherapy (RT) (combined with chemotherapy or cetuximab), the aims of this study were: (1) to identify PET-FDG parameters correlated with overall survival (OS) from a first cohort of patients; then (2) to compute a prognostic score; and (3) finally to validate this scoring system in a second independent cohort of patients.
MATERIALS AND METHODS
A total of 76 consecutive patients (training cohort from Rennes) treated with chemoradiotherapy or RT with cetuximab for LAOC were used to build a predictive model of locoregional control (LRC) and OS based on PET-FDG parameters. After internal calibration and validation of this model, a nomogram and a scoring system were developed and tested in a validation cohort of 46 consecutive patients treated with definitive RT for LAOC in Lausanne.
RESULTS
In multivariate analysis, the metabolic tumour volume (MTV) of the primary tumour and the lymph nodes were independent predictive factors for LRC and OS. Internal calibration showed a very good adjustment between the predicted OS and the observed OS at 24 months. Using the predictive score, two risk groups were identified (median OS 42 versus 14 months, p < 0.001) and confirmed in the validation cohort from Lausanne (median OS not reached versus 26 months, p=0.008).
CONCLUSIONS
This is the first report of a PET-based nomogram in oropharyngeal cancer. Interestingly, it appeared stronger than the classical prognostic factors and was validated in independent cohorts markedly diverging in many aspects, which suggest that the observed signal was robust.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1016/j.ejca.2017.01.018
- PMID 28237868
- Persistent URL
- https://sonar.ch/global/documents/257696
Export to…
Statistics
Document views: 50
File downloads:
- Full-text: 0